Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIII

16 Nov 2010

Abstract excerpt

Patients with hemophilia A present with spontaneous and sometimes life-threatening bleeding episodes that are treated using blood coagulation factor VIII (fVIII) replacement products. Although effective, these products have limited availability worldwide due to supply limitations and product costs, which stem largely from manufacturing complexity. Current mammalian cell culture manufacturing systems yield around...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Hemophilia Treatment and Research
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21081907
DOI: 10.1038/mt.2010.239

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIIIPMID 21081907Read ↗

SK-HEP cells and lentiviral vector for production of human recombinant factor VIIISemantic proximity Read ↗

Comparison of Factor VIII Transgenes Bioengineered for Improved Expression in Gene Therapy of Hemophilia ASemantic proximity Read ↗

Bioengineering of coagulation factor VIII for improved secretion.Semantic proximity Read ↗

Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid processSemantic proximity Read ↗

Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia ASemantic proximity Read ↗

Production of lentiviral vectorsSemantic proximity Read ↗

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy EfficiencySemantic proximity Read ↗

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapySemantic proximity Read ↗

The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristicsSemantic proximity Read ↗

Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.Semantic proximity Read ↗

Delivery of Full-Length Factor VIII Using a piggyBac Transposon Vector to Correct a Mouse Model of Hemophilia ASemantic proximity Read ↗

Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free MediaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.